View in EDS

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.

Saved in:
Bibliographic Details
Title: Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Authors: Adams, S1 (AUTHOR) sylvia.adams@nyumc.org, Loi, S2 (AUTHOR), Toppmeyer, D3 (AUTHOR), Cescon, D W4 (AUTHOR), Laurentiis, M De5 (AUTHOR), Nanda, R6 (AUTHOR), Winer, E P7 (AUTHOR), Mukai, H8 (AUTHOR), Tamura, K9 (AUTHOR), Armstrong, A10 (AUTHOR), Liu, M C11 (AUTHOR), Iwata, H12 (AUTHOR), Ryvo, L13 (AUTHOR), Wimberger, P14 (AUTHOR), Rugo, H S15 (AUTHOR), Tan, A R16 (AUTHOR), Jia, L17 (AUTHOR), Ding, Y17 (AUTHOR), Karantza, V17 (AUTHOR), Schmid, P18 (AUTHOR)
Source: Annals of Oncology. Mar2019, Vol. 30 Issue 3, p405-411. 7p. 3 Charts, 1 Graph.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy518